Labcorp Stock Drops 3.3% on Medicare Reimbursement Cuts: Is the Sell-Off Overdone?

Labcorp Holdings (LH) saw its stock fall 3.3% in early trading Tuesday after the Centers for Medicare & Medicaid Services (CMS) announced a significant reduction in reimbursement rates for lab services. The agency disclosed that it has been paying about 16% more for lab work than private insurers, and it plans to correct this disparity.

Effective January 1, 2027, CMS will cut reimbursement rates for lab costs by up to 15%. The agency estimates these cuts will save taxpayers $1 billion annually. However, for Labcorp, this means a direct hit to its revenue stream.

In its latest 10-K filing, Labcorp identified reductions in Medicare and Medicaid reimbursement rates as a key risk, warning that such actions could materially impact revenues, profitability, and cash flows. The company disclosed that approximately 8% of its 2025 revenue came from CMS reimbursement.

Based on this, a 15% cut to an 8% revenue stream would reduce Labcorp's annual revenue by about 1.2%. If CMS implements successive 15% cuts from 2027 through 2029, the worst-case scenario would be a cumulative 3.6% reduction in revenue.

With the stock down 3.3% today, the market appears to have already priced in this worst-case scenario, suggesting limited further downside from this news alone.

The CMS reimbursement cuts directly affect Labcorp's top line, but the magnitude is relatively small. With only 8% of revenue tied to CMS, even a 15% cut translates to a 1.2% annual revenue headwind. The potential for additional cuts through 2029 could compound the impact to 3.6%, but that remains manageable for a company of Labcorp's size and diversification.

Investors should note that Labcorp has other growth drivers, including its diagnostics and drug development businesses, which could offset these cuts. The stock's reaction today—falling 3.3%—suggests the market has quickly digested the news and adjusted expectations.

From a competitive standpoint, these cuts affect all lab companies that rely on Medicare and Medicaid reimbursements, so Labcorp is not alone. However, its relatively low exposure to CMS revenue may make it more resilient than peers with higher government payer mix.

Looking ahead, the key question is whether CMS will implement further cuts beyond 2027. If the agency follows through with successive reductions, Labcorp may need to find cost efficiencies or pass on some costs to other payers. But for now, the worst-case scenario appears to be priced in, and the stock could stabilize or rebound as investors focus on the company's long-term fundamentals.